Operating Income - Corcept Therapeutics Inc (NASDAQ:CORT) - Alpha Spread

Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 43.93 USD 1.5% Market Closed
Market Cap: 4.8B USD
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

Corcept Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Corcept Therapeutics Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Corcept Therapeutics Inc
NASDAQ:CORT
Operating Income
$128m
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$11.1B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Operating Income
$10.8B
CAGR 3-Years
-11%
CAGR 5-Years
23%
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Operating Income
$17.9B
CAGR 3-Years
21%
CAGR 5-Years
7%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Operating Income
$13.4B
CAGR 3-Years
25%
CAGR 5-Years
19%
CAGR 10-Years
12%

See Also

What is Corcept Therapeutics Inc's Operating Income?
Operating Income
128m USD

Based on the financial report for Jun 30, 2024, Corcept Therapeutics Inc's Operating Income amounts to 128m USD.

What is Corcept Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
7%

Over the last year, the Operating Income growth was 29%. The average annual Operating Income growth rates for Corcept Therapeutics Inc have been 6% over the past three years , 7% over the past five years .

Back to Top